GlobeNewsWire
10 Jul 2026, 13:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
GRAIL's NHS-Galleri trial failed to meet its primary endpoint of achieving a statistically significant reduction in Stage III-IV cancers. — Failure to meet a primary clinical endpoint for a core product directly undermines the company's value proposition and commercial prospects.
-0.90Berger Montague has filed a class action lawsuit against GRAIL alleging the company failed to disclose trial insufficiencies and adverse trends. — Securities litigation creates additional financial liability and reputational risk, though the underlying trial failure is the primary driver of value loss.
-0.40GRAIL acknowledged that a longer follow-up period would likely be needed to draw adequate comparisons between study arms. — This indicates a delay in the timeline for potential regulatory approval or market adoption, extending the period of cash burn without a definitive win.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is the subject of a class action lawsuit announcement.
The company is facing a class action lawsuit following a 50% stock price crash after failing to meet a primary clinical trial endpoint.
The company is the subject of a class action lawsuit announcement.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
